Tuttiquotidiani is completely free. Every day we aggregate news from 100+ sources and generate original AI summaries for you. Help us keep the service running with a small donation, or become TQ Pro for just €1/month.

Donate now TQ Pro - 1€/mo

Goldman Sachs Top Pharma Picks: Piramal and Syngene may see upto 26% upside but Dr Reddy’s faces 21% downside

Posted on July 9, 2026
By Financial Express
0 Views
1 min read

Goldman Sachs Top Pharma Picks: Piramal and Syngene may see upto 26% upside but Dr Reddy’s faces 21% downside

Goldman Sachs has picked Piramal Pharma, Syngene and Divi's as its preferred pharma bets ahead of Q1FY27 earnings while warning that margin pressure and fading Revlimid gains could weigh on several peers.